
Orion Pharma at ISICEM 2013



Satellite Symposium: Therapeutic Strategies to Facilitate Cardiac Postoperative Care in the ICU

- Location: Copper Hall
- Chairpersons: Jean Mantz (Paris, France) & Robert Sladen (New York, USA)
- Time: March 20, 2013 at 18:15

Programme (18:15-19:45)

- Introduction
 - Dan Longrois (Paris, France)
- Postoperative Cardiac Function: The role of levosimendan
 - Sonja Fruhwald (Graz, Austria)
- Postoperative Cardiac Comfort: Dexmedetomidine as a platform for success
 - Robert Sladen (New York, USA)
- Discussion & Questions

About Orion Pharma

Orion is a globally operating Finnish pharmaceuticals company. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion Pharma's critical care product portfolio includes two own proprietary molecules, the alpha2-agonist dexmedetomidine (**Dexdor®**) for sedation of patients in intensive care units and the cardioprotective inodilator levosimendan (**Simdax®**) for treatment of acute heart failure.

To find out more please visit **Orion Pharma at ISICEM 2013, stand nr. 2.33 - 2.38** or visit: <http://www.orion.fi/en/>

Additionally you can find specialised information about **Dexdor®** and **Simdax®** at: www.dexdor.eu and www.simdax.com

Published on : Thu, 14 Mar 2013